Continuation and Expansion of the Drug Induced Liver Injury Network(PHILLY-DILIN)

药物性肝损伤网络的延续和扩展（PHILLY-DILIN）

• 批准号: 7693777
• 负责人: VICTOR J NAVARRO
• 金额: $ 25.37万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-30 至 2013-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7693777
• 关键词: Acute; Adult; Amoxicillin; Applications Grants; Blood; Cessation of life; Childhood; Chronic; Clavulanate; Clinical; Clinical Data; Consensus; Coupled; Data Collection; Data Quality; Delaware; Detection; Development; Disease; Funding; Grant; Health Personnel; Health system; Healthcare Systems; Hepatic; Hepatology; Injury; Internet; Liver; Maintenance; Maryland; New Jersey; Patients; Pennsylvania; Pharmaceutical Preparations; Pharmacogenetics; Pharmacologic Substance; Phenytoin; Philadelphia; Population Heterogeneity; Provider; Quality of life; Reporting; Research Personnel; Resolution; Resources; Sampling; Specimen; Symptoms; System; Tissues; United States National Institutes of Health; Universities; Urine; Valproic Acid; Work; base; case-based; isoniazid; liver transplantation; member; prospective; socioeconomics; web site

DESCRIPTION (provided by applicant): The Drug Induced Liver Injury Network (DILIN), funded by the National Institutes of Health in 2002, represents a critical strategy to mitigate the adverse consequences of DILI. Already, this extensive network of centers around the U.S. has cultivated an impressive repertoire of case-based clinical information and samples which will broaden our understanding of DILI. Initial work centered around retrospective data collection on DILI attributable to four drugs; amoxicillin/clavulanate, valproic acid, phenytoin, and isoniazid. Subsequent work, which is ongoing, involves the prospective accrual of incident cases of DILI from any drug or complementary and alternative medication. The purpose of this grant application is to contribute to the expansion of the DILIN through the participation of a large Philadelphia-based consortium; the Jefferson and University of Pennsylvania Health Systems represent the largest and second largest health care systems in the region, respectively. They draw adult and pediatric patients with hepatic disease from the region comprising Eastern Pennsylvania, Delaware, Southern and Central New Jersey, and Northern Maryland. Hepatology leaders from these health care systems have agreed to collaborate as a single clinical center for his grant. In addition, the Geisinger Health System will participate as a subsite of Jefferson; this component will extend the consortium's reach to include a large part of central Pennsylvania. The consortium will bring to DILIN a large ethnically and socioeconomically diverse population of patients. The specific aims of this proposal are as follows: 1) To identify bona fide adult and pediatric cases of DILI within the region comprising Eastern and Central Pennsylvania, Maryland, Delaware, and Southern and Central New Jersey; 2) To validate the accuracy of disease attribution, in conjunction with other members of DILIN; 3) To support a national network of centers devoted to the advancement of pharmacogenetic and pharmacoepidemiological study of DILI, by providing clinical information and samples; and 4) To participate in the development and maintenance of a website for use as an educational resource on DILI.

描述（由申请人提供）： 该药物诱导的肝损伤网络（DILIN）于2002年由美国国立卫生研究院资助，是减轻DILI不利后果的关键策略。已经在美国，这个广泛的中心网络已经培养了一个令人印象深刻的基于病例的临床信息和样本的曲目，这将扩大我们对DILI的理解。最初的工作围绕着归因于四种药物的DILI的回顾性数据收集；阿莫西林/克拉维酸，丙戊酸，苯妥英钠和异烟肼。随后正在进行的工作涉及任何药物或补充药物和替代药物的DILI事件案件的预期应计。本赠款申请的目的是通过大型费城财团的参与来为稀释界的扩展做出贡献；杰斐逊和宾夕法尼亚大学卫生系统分别是该地区最大和第二大的卫生保健系统。他们从宾夕法尼亚州东部，特拉华州，南部和新泽西州以及马里兰州的地区吸引成人和儿科患者。这些医疗保健系统的肝病学领导者已同意合作作为其赠款的单个临床中心。此外，Geisinger Health System将作为Jefferson的亚地酒店参加；该组成部分将扩大财团的范围，包括宾夕法尼亚州中部的大部分。该财团将使大量的种族和社会经济多样化的患者人群稀释。该提案的具体目的如下：1）确定由宾夕法尼亚州东部和中部，马里兰州，特拉华州，南部和新泽西州组成的区域内的真正成人和小儿DILI案件； 2）验证疾病归因的准确性与迪林的其他成员结合； 3）通过提供临床信息和样本，支持致力于DILI的药物遗传学和药物电子学研究的国家中心网络； 4）参与网站的开发和维护，以用作DILI的教育资源。